rotigotine (Neupro)

From Aaushi
Jump to navigation Jump to search

Introduction

RECALL April 9, 2008[3]; REFROMULATED July 2012[4]

  • due to formation of rotigotine crystals in the patches
  • when the drug crystallizes, less drug is available to be absorbed through the skin & the efficacy of the product may vary
  • reformulated July 2012; re-introduced to the market[4]

Indications

* does not affect global cognition in Alzheimer's disease[7]

Dosage

No dosage adjustment with renal insufficiency

Pharmacokinetics

Adverse effects

Mechanism of action

More general terms

References

  1. http://www.fda.gov/cder/foi/label/2007/021829lbl.pdf
  2. 2.0 2.1 Prescriber's Letter 14(6): 2007 New Drug: Neupro (Rotigotine Transdermal System) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230602&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#neupro
  4. 4.0 4.1 Prescriber's Letter 19(7): 2012 Neupro Patch (Rotigotine) Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280705&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  6. 6.0 6.1 Medscape: rotigotine (Rx)Neupro http://reference.medscape.com/drug/neupro-rotigotine-343039
  7. 7.0 7.1 7.2 Koch G et al Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer DiseaseA Randomized Clinical Trial. JAMA Netw Open. 2020;3(7):e2010372 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32667654 Free article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2768248